(MENAFN- GetNews) "PCSK9 Inhibitors Market"The PCSK9 Inhibitors market size reached ~USD 2 billion in 2023 in 7MM and is ...

A simple scan could provide a more accurate picture of your heart attack risk than traditional assessments alone.

Heart disease is the leading cause of death in the United States. But about 80 percent of cases are considered preventable.

Repatha (Evolocumab): Amgen Repatha (Evolocumab) is a PCSK9 inhibitor used for lowering LDL cholesterol in patients with Atherosclerotic Cardiovascular Disease (ASCVD) who require additional lipid ...

Most Medicare Part D (prescription drug) plans cover Repatha (evolocumab). However, because private insurers provide Part D plans, coverage may vary by plan. Repatha coverage with Medicare Part C ...

The agent tested in the present study, evolocumab (Repatha), was first FDA approved in 2015 and has since also won an indication for cardiovascular prevention.

BARCELONA, SPAIN—Long-term treatment with evolocumab (Repatha; Amgen) is associated with a significant reduction in clinical outcomes, including cardiovascular mortality, compared with patients who ...

A clinical trial led by investigators from Brigham and Women’s Hospital has found that the long-term use of the cholesterol lowering drug evolocumab was safe, well tolerated, and led to further ...

A phase 0/surgical window-of-opportunity study in progress, evaluating evolocumab in patients with high-grade glioma or glioblastoma.. If you have the appropriate software installed, you can download ...